BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

miRagen Therapeutics Secures $20 Million Series B Financing


4/24/2012 7:08:03 AM

BOULDER, Colo.--(BUSINESS WIRE)-- MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today the completion of a $20 million Series B financing. The financing is being led by Remeditex Ventures, LLC, with participation from miRagen’s existing investor syndicate, which includes Atlas Venture, Boulder Ventures Ltd., Amgen Ventures, and Broadview Ventures. The funding enables miRagen to advance the development of its compelling microRNA-based therapeutics pipeline.

“The Series B financing provides further validation of miRagen and the promise of microRNA-based therapeutics,” said William S. Marshall, Ph.D., President and Chief Executive Officer. “This funding strengthens our ability to advance novel microRNA-based therapeutics that may address areas of high unmet medical need and improve the lives of patients. We are thankful to have a committed syndicate of investors and excited to welcome Remeditex to the team.”

“In a short period of time, miRagen has delivered significant advances that help to translate new biology into next generation therapeutic candidates,” said Bruce Booth, D.Phil., miRagen’s Chairman of the Board and Partner, Atlas Venture. “The team has generated these compelling results in a capital efficient manner, and we look forward to moving the company to the logical next level with the Series B investment.”

“We are excited to be a part of the high quality team at miRagen and to help advance the company’s promising therapeutics,” said John Creecy, Chief Executive Officer and Director at Remeditex Ventures. “We believe this science can be life changing for the many that have so few options today, and that miRagen is well positioned for success in making that happen.”

About microRNAs: MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are associated with many disease processes. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes.

About miRagen Therapeutics: MiRagen Therapeutics, Inc., is a biopharmaceutical company founded to harness the power of microRNA (miRNA) biology and develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. In October 2011, miRagen and Les Laboratoires Servier, a leading European pharmaceutical company, entered into a strategic alliance for the research and development of microRNA-based therapeutics for the treatment of patients afflicted with cardiovascular disease. Combining in-house expertise in microRNA biology and chemistry with strong external partnerships and academic collaborations, miRagen is striving to make a difference in health care across the globe. For more information, please visit www.miragenrx.com.

Contact:

For miRagen

Kecia Carroll, Communications

720-933-0848

Kecia@kcroberg.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES